Italia markets closed

Supernus Pharmaceuticals, Inc. (0LB2.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a portafoglio
55,00+22,00 (+66,67%)
Alla chiusura: 6:00AM GMT
Schermo intero
Chiusura precedente33,00
Aperto34,22
Denaro0,00 x 0
Lettera0,00 x 0
Min-Max giorno34,22 - 34,22
Intervallo di 52 settimane34,22 - 34,22
Volume8.178
Media VolumeN/D
Capitalizzazione2,457B
Beta (5 anni mensile)1,20
Rapporto PE (ttm)36,47
EPS (ttm)1,51
Prossima data utili23 feb 2022 - 28 feb 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Supernus Pharmaceuticals Targeted in Ransomware Incident

    The attack had no significant impact on the business and did not cause any significant disruption to Company’s operations No ransom payments have been made by the Company ROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a biopharmaceutical company, today announced that it was the recent target of a ransomware attack. The attack had no significant impact on the business and did not cause any serious disruption to the Company’s operations. The Compan

  • GlobeNewswire

    Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals

    Acquisition strengthens Parkinson’s disease portfolio and diversifies revenue and cash flowROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). “Adamas fits squarely within our corporate development strategy, adding a late-stage commercial product with significant revenue,” said Jack Khattar, President and CEO of Supern

  • GlobeNewswire

    Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer

    ROCKVILLE, Md., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Supernus’ proposed acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) expired at 11:59 p.m. on November 22, 2021. On October 21, 2021, Supernus and Adamas filed the Premerger Notification and Report Forms required under the HSR Act with the Federal Trade Com